The urgency behind the new assays is difficult to overstate. Since its first detection in January 2022, highly pathogenic avian influenza H5 has infected more than 13,000 wild birds and roughly 173 million poultry, with economic losses estimated between 14 and 164 billion dollars. In March 2024, an unprecedented spillover of clade 2.3.4.4b A(H5N1) into dairy cattle was reported in Texas, and the virus has since spread across 17 US states, infecting more than 1,000 cattle herds with sustained mammalian transmission and 70 human cases reported as of June 3, 2025. Historically, HPAI outbreaks such as H5N1 in Hong Kong in 1997 and H7N9 in China in 2013 have produced case fatality rates of at least 30 percent in humans, underscoring the pandemic potential that hangs over every new host adaptation.

Current diagnostic approaches each carry trade-offs that limit their usefulness in the field. Virus isolation remains the gold standard but is confined to biosafety level-3 laboratories staffed by highly trained personnel. Rapid immunoassays deliver results in about 15 minutes but suffer from reduced sensitivity and cannot discriminate between viral clades. Reverse transcription PCR offers high sensitivity and adaptability yet depends on thermocycling equipment and skilled operators, while next-generation sequencing provides nucleotide-level resolution at the cost of high expense and long turnaround times. The result, the authors argue, is a diagnostic landscape in which the tools that respond fastest to outbreaks are either too insensitive or too infrastructure-dependent to support surveillance at farms, markets, and rural clinics where spillovers first emerge.

To close this gap, the team turned to SHINE, short for Streamlined Highlighting of Infections to Navigate Epidemics, a one-pot CRISPR diagnostic platform previously developed for SARS-CoV-2 and influenza detection. In the avian influenza version of the workflow, viral RNA undergoes reverse transcription, recombinase polymerase amplification, and T7 transcription within a single tube, generating RNA amplicons that activate the collateral cleavage activity of the Cas13a enzyme when they base-pair with a complementary CRISPR RNA guide. Activated Cas13a then cuts RNA reporters, producing either a fluorescent signal read out on a plate reader or a colorimetric band on a paper lateral flow strip, the latter requiring nothing more sophisticated than a smartphone camera to document.

Assay design leaned heavily on machine learning. The researchers used ADAPT, a software platform that predicts sensitive and specific Cas13 guide sequences, to select primer and crRNA sets targeting the hemagglutinin gene segment that uniquely defines H5 viruses. Two candidate designs achieved predicted coverage of 98.72 and 96.18 percent of aligned H5N1 sequences, and the top-performing guide, targeting nucleotides 847 to 874 of the H5 consensus, was carried forward. A series of optimization experiments followed: the team tuned the ratio of T7-attached to non-T7-attached forward primers, settled on a 1:3 ratio that reduces competition between amplification and detection, increased RPA primer concentrations, and adjusted reporter, RNase H, and magnesium levels. The resulting optimized assay, SHINE-H5, reliably detected synthetic RNA targets across all tested concentrations within 60 minutes, a substantial improvement over the prototype.

Analytical characterization of SHINE-H5 was rigorous. Testing against six vaccine-derived viral seedstocks from the CDC showed high fluorescence for the intended target and negligible signal for non-target viruses. Clinical specificity was evaluated using 64 nasopharyngeal swab specimens from Massachusetts General Hospital that tested positive for seasonal influenza A or B but negative for avian H5 by qPCR; SHINE-H5 correctly returned negative results for all 64 samples, covering infections with H1N1, H3N2, and influenza B, including co-infections. The limit of detection, established with serial dilutions of H5N1 viral seedstock in viral transport media and a logistic regression model requiring at least 95 percent detection, was 121.7 copies per microliter, with a 95 percent confidence interval of 63.14 to 234.55 copies per microliter. In a head-to-head comparison, a validated RT-qPCR assay detected samples down to 10 copies per microliter while SHINE-H5 detected down to 50 copies per microliter, a sensitivity gap the authors acknowledge but one that still significantly outperforms existing H5 immunoassays.

For field deployment, the researchers adapted SHINE-H5 to a lateral flow readout, replacing the fluorescent quenched reporter with a FAM-biotin reporter whose cleavage products migrate on a paper strip. Using a larger 40-microliter reaction volume, the lateral flow version detected H5N1 seedstock down to 25 copies per microliter while retaining strong specificity against a subset of 14 seasonal influenza-positive patient samples. The team also demonstrated that the assay can detect synthetic RNA targets spiked into milk, a proof of concept for surveillance in the dairy herds now at the center of the North American outbreak.

Beyond broad H5 detection, the study introduces SHINE-H5-CS, a clade-specific assay targeting 2.3.4.4b A(H5N1), the lineage that has dominated global H5 phylogeny since 2021 and is driving the US cattle outbreak. Guide design for this assay employed BADGERS, a successor to ADAPT that integrates advanced search algorithms to explore the fitness landscape of candidate crRNAs and achieve single-nucleotide discrimination. Of three candidates, crRNA3, targeting a region of the H5 segment starting at nucleotide position 880, showed the highest on-target activity with minimal off-target signal. The researchers also shifted the forward primer four nucleotides upstream to introduce an additional mismatch that sharpened discrimination. SHINE-H5-CS consistently detected clade 2.3.4.4b RNA at concentrations above 100 copies per microliter while showing minimal cross-reactivity with non-2.3.4.4b H5 sequences and seasonal influenza seedstocks, enabling lineage identification without sequencing.

The team extended the platform to the H7 subtype, the other hemagglutinin group with well-documented potential to evolve into highly pathogenic strains. Phylogenetic analysis of 25 representative H7 strains revealed clean separation into Eurasian and North American lineages that mirror migratory bird flyways, and the 2013 Eurasian H7N9 epidemic, which caused more than 1,500 human infections with a fatality rate near 40 percent, demonstrated the public health stakes of this lineage. The resulting SHINE-H7-Eurasian assay reliably detected Eurasian H7 RNA across a range of concentrations while discriminating against North American H7 strains and a panel of unrelated seasonal influenza viruses, and it too was adapted to a lateral flow format that preserved lineage specificity.

The authors are candid about the limitations of the work. Confirmed human H5 and Eurasian H7 cases remain rare, so the assays could not be evaluated on true positive human clinical specimens, and compatibility with specimen types beyond mock milk samples, such as poultry or environmental samples, has not yet been assessed. Even so, the combination of isothermal operation at 37 degrees Celsius, turnaround times of 60 to 120 minutes, minimal instrumentation, machine-learning-accelerated assay design, and compatibility with paper-based readouts positions the SHINE family of assays as a practical bridge between laboratory-grade accuracy and point-of-need accessibility. As avian influenza continues its advance through wild birds, poultry, cattle, and occasionally people, tools that can detect not just the virus but its specific clades, close to where it emerges, may prove decisive in blunting the next spillover before it becomes the next pandemic.

Subject of Research: Development of streamlined one-pot CRISPR-Cas13 diagnostic assays for detection and genetic subtyping of H5 and H7 avian influenza viruses

Article Title: Streamlined CRISPR-based assays for detection and subtyping of H5 and H7 avian influenza

Article References: Huang, Y., Guo, A., Adams, G., Lemieux, J. E., & Myhrvold, C. (2026). Streamlined CRISPR-based assays for detection and subtyping of H5 and H7 avian influenza. iScience, 29(10), Article 117556. https://doi.org/10.1016/j.isci.2026.117556

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117556

Keywords: avian influenza, CRISPR diagnostics, SHINE assay, Cas13, H5N1, H7 avian influenza, clade 2.3.4.4b, lateral flow assay, recombinase polymerase amplification, point-of-need testing, dairy cattle outbreak, pandemic preparedness

The power of CRISPR rests on its molecular logic. At its core, the system pairs a programmable guide RNA with a Cas nuclease, allowing researchers to target almost any DNA or RNA sequence with single-base precision. Since the foundational demonstration that Cas9 can be directed by a dual-RNA guide to cleave chosen genomic sites, the toolbox has expanded dramatically. Base editors now rewrite individual letters of the genetic code without making double-strand breaks, prime editors perform search-and-replace genome surgery without donor DNA templates, and dead Cas proteins fused to regulatory domains can silence or activate genes without cutting at all. RNA-targeting variants such as Cas13 extend the approach to transcriptomes, while Cas12a’s collateral cleavage activity has become the engine of a generation of ultrasensitive diagnostic platforms. This versatility is precisely what makes the technology attractive for environmental applications, where targets are diverse, distributed, and constantly evolving.

Perhaps the most mature environmental application involves turning CRISPR against its own microbial relatives. Because guide RNAs can be designed to discriminate between strains at the level of single nucleotides, CRISPR-Cas systems can be deployed as sequence-specific antimicrobials that eliminate pathogenic or antibiotic-resistant bacteria while sparing benign members of a microbial community. Studies have shown that genome-targeting CRISPR-Cas constructs can programmatically remove defined bacterial strains from mixed populations, offering a selectivity that broad-spectrum antibiotics and disinfectants cannot match. Engineered bacteriophages carrying CRISPR payloads can deliver these constructs directly into target cells, and combinations of CRISPR-Cas9 with nanoparticle delivery systems are being explored against stubborn biofilm-driven infections. Researchers have also documented the flip side: bacteria can mount resistance to CRISPR antimicrobials, and anti-CRISPR proteins found in mobile genetic elements can neutralize the systems, underscoring that deployment strategies must anticipate evolutionary pushback.

Antibiotic resistance genes represent a particularly insidious form of biological pollution because they spread horizontally through water systems, soils, and food chains. The review highlights how CRISPR-based interventions could excise or disrupt resistance genes directly in environmental microbial communities, while CRISPR-enabled diagnostics provide the surveillance backbone needed to track them. Field-deployable assays that pair Cas12a or Cas13a with isothermal amplification methods such as LAMP and RPA have already been used to detect antibiotic resistance genes like ermB in wastewater and to identify SARS-CoV-2 in sewage, sometimes on paper-based devices read by smartphone. These platforms turn what once required a fully equipped molecular laboratory into tests that can run at the entrance of a treatment plant or in a monitoring van, closing the feedback loop between detection and intervention.

Pathogen surveillance extends beyond resistance genes. The authors describe CRISPR diagnostic platforms, sometimes called CRISPR-Dx, as complementary tools for identifying and tracking biological contaminants in real time. Portable plasmonic biosensors coupled with Cas12a have been used for genotyping SARS-CoV-2 in sewage, and one-pot, amplification-free RNA detection has been demonstrated with the newer Cas12a2 variant. Work from the review’s own research group, including the WATER NEWS field approach for sustainable pathogen detection in wastewater and optimized monitoring scenarios for resistance genes in urban water cycles, illustrates how these diagnostics can be tuned for routine environmental practice. In a world still digesting the lessons of pandemic wastewater monitoring, the ability to read the genetic signature of contamination quickly, cheaply, and on site is a quiet revolution in public health infrastructure.

Against invasive and harmful species, CRISPR offers interventions of a different scale. Gene drive systems, which bias inheritance to spread engineered traits through wild populations, have been built to target female reproduction in the malaria mosquito Anopheles gambiae and have produced complete population suppression in caged mosquito experiments. Precision-guided sterile insect approaches have eliminated malaria vectors in laboratory trials and been demonstrated in flies, while split drive designs targeting the doublesex gene are being pursued against the invasive malaria vector Anopheles stephensi and the global fruit pest Drosophila suzukii. Similar logic applies to agricultural pests: CRISPR-Cas9 has been used to validate spermatogenesis genes as targets in the fall armyworm, one of the world’s most damaging invasive insects, and to edit fall armyworm genomes for future population control.

Plants are being recruited to the same fight, but from the defensive side. Rather than attacking pathogens directly, CRISPR edits crop genomes to remove susceptibility genes that pathogens exploit. Editing the MLO gene family in soybean, the PMR4 gene in tomato, and the CsLOB1 promoter region in grapefruit have all yielded resistance to powdery mildew, bacterial diseases, and citrus canker respectively, while edits in tomato Bs5 genes and rice OsETR haplotypes confer resistance against Xanthomonas and bacterial blight. Editing the TOM1 gene in tobacco confers resistance to tobacco mosaic virus. In several cases, Cas12a ribonucleoprotein delivery has produced transgene-free, canker-resistant citrus lines, sidestepping some regulatory and public acceptance issues associated with introducing foreign DNA. The review frames these crop edits as a form of biological pollution control that reduces pesticide dependence and the ecological damage that follows chemical-intensive disease management.

Yet the authors are explicit that laboratory success does not translate automatically into environmental impact. Delivery remains the central technical bottleneck: getting CRISPR components to the right cells in a lake, a soil horizon, or an insect population in the open field is vastly harder than transfecting a cell culture. Viral vectors, polymer nanocomplexes, and nonviral nanoparticles, including high-loading porous silicon and polymer systems capable of in vivo Cas9 delivery, are promising but unproven at ecosystem scale. Off-target editing risks harming non-target organisms, and even perfectly targeted edits can have unpredictable consequences when released into complex ecological networks. Horizontal gene transfer, resistance evolution, and the sheer heterogeneity of environmental matrices all compound the difficulty. The review also stresses governance: gene drives in particular demand regulatory frameworks capable of assessing irreversible, cross-border ecological interventions, and public trust will hinge on transparency, containment strategies such as daisy-chain and split drives that limit spread, and responsible oversight.

Looking forward, the authors identify three converging directions. High-precision editing tools, including improved base editors with widened targeting range and engineered Cas variants with expanded PAM compatibility and higher fidelity, will reduce collateral damage. Intelligent delivery systems, potentially combining engineered phages, nanoparticles, and biosensors that release payloads only upon detecting their targets, will improve spatial and temporal control. And emerging artificial intelligence approaches, from deep learning models that predict guide RNA efficiency to AI-designed editor proteins, could accelerate the design of environmentally tailored systems. Together with a maturing governance discourse, these advances suggest a pathway from demonstration projects to genuine deployment, provided researchers treat ecological uncertainty as a design constraint rather than an afterthought.

The significance of the review lies less in any single result than in the synthesis it offers. Biological pollution is compounding: resistance genes accumulate in water cycles, invasive pests reshuffle global agriculture, and pathogens exploit every corridor of trade and climate change. Conventional chemical and physical controls are reaching their limits, often trading one harm for another. CRISPR, the authors argue, is the first technology that matches this problem’s defining feature, which is specificity, allowing interventions aimed precisely at the pathogen, the resistance gene, or the invader while leaving the surrounding biological community intact. Whether that promise survives contact with real ecosystems will depend on the coming decade of field trials, regulatory imagination, and public engagement, but the review makes clear that the tools are no longer the limiting factor. The limiting factor is learning to use them responsibly at scale.

Subject of Research: Application of CRISPR gene-editing and diagnostic technologies for controlling environmental biological pollution, including pathogens, antibiotic resistance genes, and invasive species.

Article Title: Advances and challenges in the application of CRISPR technology for environmental biological pollution control

Article References: Zheng, X.-F., Cheng, Z.-H., Yu, H.-Q., & Liu, D.-F. (2026). Advances and challenges in the application of CRISPR technology for environmental biological pollution control. ENGINEERING Environment, 20(12), Article 187. https://doi.org/10.1007/s11783-026-2287-5

Image Credits: AI Generated

DOI: 10.1007/s11783-026-2287-5

Keywords: CRISPR-Cas, gene editing, biological pollution, antibiotic resistance, pathogen detection, invasive species, gene drive, wastewater surveillance, environmental biotechnology, bioremediation, crop disease resistance, CRISPR diagnostics

The platform, named HOMEBRED for highly sensitive and specific omnipresent multiplex endonuclease-based reliable detection, is built on the SHERLOCK architecture that harnesses the CRISPR-associated protein Cas13a. When Cas13a finds the RNA sequence its guide molecule instructs it to find, it does not merely cut the target; it shreds any nearby RNA indiscriminately. This collateral cleavage activity is the engine of the assay. Synthetic RNA reporters carrying a fluorescent dye and a quencher float in the reaction; if the target is present, the reporters are cleaved, the fluorescence escapes, and the result can be read with the naked eye under an inexpensive handheld blue light or on paper-based lateral flow strips. No thermocycler, no sequencer, no fluorescence plate reader is required at any stage.

What separates HOMEBRED from earlier CRISPR diagnostics is the way its guide RNAs are chosen. Fragile crRNA target windows have been a chronic vulnerability in CRISPR-based tests, because a single mutation in the target sequence can silence the assay entirely, allowing an evolving pathogen to escape detection. The team addressed this with CaSilico, an automated computational pipeline that screens thousands of genome sequences to identify highly conserved, mutation-resistant regions. For foot-and-mouth disease virus, one of the most genetically variable livestock pathogens known, CaSilico analyzed 707 sequences of the conserved 3D gene across all seven serotypes, applying a 98 percent conservation threshold and yielding 41 candidate target sites from which two crRNAs were selected using stringent thermodynamic and specificity criteria.

That computational rigor proved consequential in practice. One of the two initial foot-and-mouth disease virus crRNAs, CR3D1, looked ideal on paper yet failed to detect the virus in the laboratory. When the researchers examined its predicted secondary structures in detail, they found that the centroid structure, not just the minimum free energy fold, deviated from the stable hairpin architecture that Cas13a requires for recognition. This failure mode has been observed by other groups, and the finding underscores a lesson increasingly clear in the field: guide RNA design must weigh thermodynamic structure predictions as carefully as sequence conservation. The redesigned guide, CR3D2, worked flawlessly, correctly classifying all 11 clinical samples in complete agreement with reference RT-qPCR, with detection limits reaching down to ten copies per microliter in both fluorescent and lateral flow formats.

Perhaps the most consequential demonstration involves brucellosis, a bacterial zoonosis that infects an estimated 300 million of the world’s 1.4 billion cattle and for which no human vaccine exists. Veterinary control programs face a stubborn problem known as DIVA, the inability to differentiate infected animals from vaccinated ones. A false positive in a vaccinated, high-breeding-value animal can trigger needless culling, while a missed infection lets the disease spread silently. HOMEBRED tackles this with a dual-crRNA architecture: one guide targets the conserved bcsp31 gene to detect the four major Brucella species, while a second exploits a deletion mutation in the narJ gene unique to the RB51 vaccine strain. In testing, the platform signaled every wild-type culture of B. melitensis, B. abortus and B. suis while remaining silent against the vaccine strain, achieving 100 percent concordance with reference PCR across all 14 samples tested.

The platform also ventures into oncology. BCR-ABL1 fusion transcripts, produced when chromosomes 9 and 22 break and rejoin, are the hallmark of chronic myeloid leukemia, and the specific transcript isoform a patient carries influences response to tyrosine kinase inhibitor therapy. HOMEBRED distinguished the e13a2, e14a2 and e1a2 isoforms using isoform-specific guide RNAs and recombinase polymerase amplification primers sharing a common reverse primer on the ABL1 gene. Validated against the KCL-22 and K-562 leukemia cell lines and 14 clinical samples, the assay matched Sanger sequencing in specificity and exceeded RT-qPCR in sensitivity. Strikingly, three samples that reference RT-qPCR had called negative were positive by HOMEBRED, and two patients were found to co-express two transcript types simultaneously, findings with direct implications for treatment selection and minimal residual disease monitoring.

Two reaction formats were compared head to head. The two-step assay runs amplification and detection in separate tubes, while the single-step format folds both into one pot, reducing handling time and contamination risk. For Brucella, the one-pot version matched the two-step version perfectly, but for foot-and-mouth disease virus it dropped to 77 percent agreement, missing three positives and losing roughly an order of magnitude in detection limit. The authors conclude that the two-step format remains the safer default when sensitivity is paramount, reserving the single-step format for targets where its performance is proven. All duplicate reactions across both formats achieved 100 percent qualitative concordance, 111 out of 111 pairs, a reproducibility figure that speaks to careful optimization.

The extraction-free capability is where HOMEBRED pushes furthest past the existing literature. Traditional purification, when skipped, usually devastates sensitivity because crude biological matrices carry enzymatic inhibitors such as hemin and polysaccharides. The team paired their assay with HUDSON, a method that heats samples with chemical reducers to destroy nucleases and release genetic material, and applied it directly to vesicular fluid and epithelial tissue from foot-and-mouth disease cases. Without any nucleic acid extraction, the workflow detected viral seedstock down to 3.23 times ten to the fourth plaque-forming units per milliliter by colorimetric readout and 3.23 times ten to the third by fluorescence, an improvement of up to two orders of magnitude over comparable extraction-free CRISPR assays. The strategic choice of epithelial tissue, which proves far more chemically compatible with the HUDSON reaction than blood or feces, appears central to this performance.

Robustness against real-world genetic drift was verified by sequencing. Sanger analysis of foot-and-mouth disease virus samples confirmed that the computationally designed target region stayed fully conserved across strains, with a single substitution in one sample that failed to impair detection. Two leukemia clinical samples harbored point mutations inside the protospacer region, and HOMEBRED still called both correctly with no signal loss. The choice of Cas13a over the Cas12a enzymes used in several rival platforms also matters here: Cas13a requires no protospacer adjacent motif, freeing guide design from target-site constraints that are particularly restrictive when isolating the narrow junctions of fusion transcripts, and its vigorous trans-cleavage activity sustains signal generation even at suboptimal temperatures.

The authors acknowledge limits. Clinical isolates of B. canis could not be physically tested due to regional availability, so the team verified the assay against synthetic DNA carrying the identical conserved bcsp31 target domain, supported by sequence alignments showing 100 percent identity. No accessible cell line expressing the minor e1a2 transcript was available for extended in vitro benchmarking. Future work, they write, should prioritize lyophilized reagent formulations to round out farm-level deployment. Even with those caveats, HOMEBRED demonstrates that a single CRISPR platform, guided by automated conserved-region design and read by nothing more sophisticated than a handheld blue light, can deliver sensitivity on par with PCR across livestock pathogens, zoonotic bacteria, respiratory viruses and leukemia biomarkers, a convergence that could materially narrow the diagnostic gap between well-resourced laboratories and the places where early detection matters most.

Subject of Research: A CRISPR-Cas13a diagnostic platform enabling instrument-free detection of infectious agents and oncogenic mutations

Article Title: HOMEBRED: A unified CRISPR platform for field-ready shadowing of infectious agents and oncogenic mutations

Article References: Asadbeigi, A., Fazilaty, H., Saffari, M., Shirkoohi, R., Modarressi, M. H., Salehi, A., & Bakhtiarizadeh, M. R. (2026). HOMEBRED: A unified CRISPR platform for field-ready shadowing of infectious agents and oncogenic mutations. iScience, 29(10), Article 117532. https://doi.org/10.1016/j.isci.2026.117532

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117532

Keywords: CRISPR diagnostics, Cas13a, SHERLOCK, HOMEBRED, foot-and-mouth disease virus, brucellosis, SARS-CoV-2, BCR-ABL1, chronic myeloid leukemia, recombinase polymerase amplification, DIVA, point-of-care testing

The analysis, covering publications from 2000 to 2025, drew on the Scopus database and followed a PRISMA-adapted screening workflow to construct a final analytical corpus of 1,746 articles and reviews spanning 432 journals and involving 11,277 unique authors. The field has expanded at a compound annual growth rate of 17.10%, accumulating 42,075 citations with an average of 24.10 citations per document. Growth accelerated sharply after 2018: annual output rose from 84 publications in 2018 to 259 in 2025, a trajectory the study attributes to increasing prioritization of antimicrobial resistance on the global research agenda and a post-pandemic surge in translational diagnostic research.

To frame the analysis, the study anchored itself in the World Health Organization’s bacterial priority pathogen lists. The WHO’s 2017 framework classified resistant bacteria into critical, high, and medium priority categories, and its 2024 update expanded the list to 24 pathogens across 15 bacterial families using multicriteria decision analysis that weighed mortality, incidence, resistance trends, transmissibility, preventability, treatability, and the state of the drug development pipeline. The critical tier now includes carbapenem-resistant Acinetobacter baumannii, carbapenem-resistant and third-generation cephalosporin-resistant Enterobacterales, and rifampicin-resistant Mycobacterium tuberculosis, while carbapenem-resistant Pseudomonas aeruginosa was moved from critical to high priority based on regional resistance trends and comparatively lower transmission capacity.

Against this backdrop, the bibliometric results reveal a field organized around distinct pathogen axes. Staphylococcus aureus dominated the corpus with 730 publications and 21,945 total citations, followed by Mycobacterium tuberculosis with 439 publications, Enterobacterales with 389, Pseudomonas aeruginosa with 309, Acinetobacter baumannii with 279, and Enterococcus faecium with 250. Growth over the past five years was strongest for Streptococcus pneumoniae at 27.79%, Pseudomonas aeruginosa at 26.35%, and Enterobacterales at 22.81%, signaling a decisive shift in research attention toward Gram-negative carbapenem resistance as the most urgent clinical frontier.

At the platform level, conventional PCR and nucleic acid amplification testing appeared in 61.51% of publications, while whole-genome sequencing featured in 55.44%, making these two technologies the twin pillars of the literature. Because platform categories were not mutually exclusive, many publications combined both approaches. Multiplex PCR stood out for impact, averaging 42.57 citations per article, reflecting the foundational role of early target-specific resistance detection. Emerging technologies, including nanopore sequencing, metagenomic sequencing, and CRISPR-based diagnostics, appeared at low frequencies but formed distinct and growing clusters, suggesting they represent innovation fronts that have not yet reached routine clinical integration.

Resistance marker analysis identified mecA/mecC, rpoB, blaNDM, katG, and vanA/vanB as the most frequently studied molecular targets. Methicillin resistance in staphylococci, epitomized by the mecA gene and its newer variant mecC, anchored the Gram-positive research tradition, while the tuberculosis markers rpoB, katG, and inhA defined a mature and specialized diagnostic axis. Carbapenemase genes, including blaKPC, blaNDM, and blaOXA-48, together with the mobile colistin resistance gene mcr and the fluoroquinolone targets gyrA and parC, showed the strongest recent growth, with gyrA and parC expanding at compound annual rates of 44.28% and 49.53% respectively over the last five years.

Thematic mapping of keyword co-occurrence networks revealed that the literature is structured around six interpretable clusters. Two emerged as mature core themes: PCR-based rapid antimicrobial resistance detection, organized around MRSA, multiplex PCR, and the mecA/mecC and vanA/vanB markers, and a whole-genome sequencing and genomic epidemiology theme spanning multiple pathogen groups. The tuberculosis resistance marker axis formed a strong but specialized mature theme, while the carbapenemase and Gram-negative resistance gene cluster, the metagenomic and nanopore clinical diagnostics cluster, and a general cross-pathogen antimicrobial resistance cluster were identified as emerging or niche research fronts.

Thematic evolution analysis across three time windows documented a clear conceptual restructuring. The early period from 2000 to 2010 centered on target-specific markers such as mecA, vancomycin resistance, and real-time PCR, reflecting an era of single-gene rapid tests. The middle period from 2011 to 2020 brought whole-genome sequencing, tuberculosis, multiplex PCR, and the Enterobacterales-carbapenemase axis to prominence. The recent period from 2021 to 2025 represents a more integrated antimicrobial resistance framework in which WGS, Staphylococcus aureus, and antibiotic resistance concepts dominate, demonstrating the field’s transition from individual marker detection to genomically integrated, translationally oriented diagnostics.

The study’s methodological rigor included a validation exercise in which 150 randomly selected records were blindly reassessed to test the rule-based text-matching system used to classify pathogens, platforms, markers, and clinical contexts. Concordance rates reached 100% for platform and resistance-marker labels, 91.3% for pathogen labels, and 86.7% for clinical-context labels, yielding an overall average agreement of 94.5%. The analysis also mapped the geography of the field: China led production with 263 publications, followed by the United States with 252, the United Kingdom with 130, and Germany with 127, though the United Kingdom and France showed higher rates of international collaboration and network centrality, revealing a divide between volume-based productivity and collaboration-intensive influence.

The findings carry important implications for clinical practice. Prior evidence shows that rapid diagnostic tests, when deployed alongside antimicrobial stewardship programs, reduce mortality in bloodstream infections compared with blood culture alone. The bibliometric structure documented here confirms that molecular diagnostics has evolved beyond answering whether a pathogen is present, into a multilayered data-generating enterprise that supports resistance prediction, monitoring of clonal spread, and clinical and public health decision-making. At the same time, the study acknowledges limitations: PCR panels and WGS report genetic content rather than physiological state, meaning phenomena such as bacterial persistence and tolerance fall largely outside the field’s marker-centered vocabulary, and future work integrating phenotypic, genomic, and virulence-layer data will be essential to close the gap between resistance prediction and treatment outcome.

Subject of Research: Bibliometric mapping of molecular diagnostic platforms and resistance markers for WHO priority bacterial pathogens

Article Title: Molecular Diagnostics for WHO Priority Bacterial Pathogens: A Bibliometric Mapping of Diagnostic Platforms, Resistance Markers, and Antimicrobial Resistance Research Trends

Article References: Ünlü, S. (2026). Molecular Diagnostics for WHO Priority Bacterial Pathogens: A Bibliometric Mapping of Diagnostic Platforms, Resistance Markers, and Antimicrobial Resistance Research Trends. MicrobiologyOpen, 15(5), Article e70394. https://doi.org/10.1002/mbo3.70394

Image Credits: AI Generated

DOI: 10.1002/mbo3.70394

Keywords: antimicrobial resistance, molecular diagnostics, WHO priority pathogens, whole-genome sequencing, PCR, bibliometric analysis, MRSA, carbapenemase genes, Mycobacterium tuberculosis, Enterobacterales, CRISPR diagnostics, genomic epidemiology

The field traces its origins to the 1980s, when Ned Seeman proposed using cross-shaped Holliday junctions as modular building blocks for larger assemblies. By adjusting the sticky ends of these four-arm junctions, researchers could link tiles into increasingly complex two-dimensional patterns, culminating in Winfree’s 1998 demonstration of 2D DNA crystals built from double-crossover tiles. The pivotal breakthrough came in 2006, when Paul Rothemund introduced DNA origami: a long single strand of bacteriophage DNA folded by hundreds of short staple strands into pre-designed shapes of roughly 100 nanometers, from simple triangles to intricate patterns. In 2012, Peng Yin’s group added a third pillar with DNA bricks—short synthetic strands that self-assemble into stable three-dimensional constructs without any long scaffold, each brick functioning as a removable module. Today, complementary strategies such as rolling circle amplification and enzyme-free reactions like hybridization chain reaction and catalytic hairpin assembly allow structural construction and signal amplification to proceed simultaneously under mild, isothermal conditions.

What makes DNA nanostructures so attractive for fighting pathogens is a constellation of biophysical properties. Their geometry can be engineered with near-atomic precision, and that geometry directly governs biological behavior. Tetrahedral DNA nanostructures (TDNs) decorated on nanoparticle cores mimic the spiky architecture of coronaviruses, boosting small interfering RNA delivery efficiency from roughly 20 percent to 95 percent. The structures enter cells through caveolin-dependent and macropinocytosis pathways despite their negative charge, with size, shape, and rigidity each modulating uptake; medium-sized, compact, three-dimensional particles generally perform best. They also penetrate remarkable biological barriers: structures of 75 nanometers or less can reach the dermis, TDNs traverse up to 450 micrometers of skin, and the structures diffuse into bacterial biofilms—the dense, antibiotic-resistant fortresses that thwart conventional therapies.

Equally striking is their antioxidant chemistry. DNA origami scavenges singlet oxygen approximately 50,000 times more efficiently than double-stranded DNA, because folded architectures concentrate guanine active sites at high density. TDNs bind the antioxidant enzyme copper-zinc superoxide dismutase with extraordinary affinity, a dissociation constant of 7.59 × 10⁻¹² molar, and can dampen oxidative stress through the Nrf2/HO-1, MAPK, and NF-κB signaling pathways. Combined with low cytotoxicity below 250 nanomolar concentrations, negligible effects on platelets and red blood cells, high drug-loading capacity through intercalation, groove binding, electrostatic adsorption, or sequence hybridization, and rapid renal clearance of small constructs, these features position DNA nanostructures as unusually benign yet capable nanocarriers.

On the diagnostic front, the review documents detection limits that routinely rival or surpass polymerase chain reaction and ELISA. DNA walkers—dynamic structures that move along programmed tracks—have been coupled with electrochemical readouts to detect Staphylococcus aureus at just 9 colony-forming units per milliliter. A polymethylene blue nanoparticle sensor built on dumbbell hybridization chain reaction pushed S. aureus detection down to a single cell per milliliter in human serum and food samples. Dual-mode photoelectrochemical and surface-enhanced Raman spectroscopy platforms now allow hierarchical screening and confirmation in complex matrices such as fruit juices, while cyclic DNA nanostructure gold nanoparticle tags combined with cascade primer exchange reactions detect E. coli O157:H7 at 1.91 colony-forming units per milliliter with recoveries between roughly 88 and 108 percent in real samples.

Against viruses, tetrahedral frameworks have proven especially powerful. TDN-supported field-effect transistors detect SARS-CoV-2 nucleic acid in about 80 seconds without extraction or amplification, reaching limits of one to two copies per 100 microliters of clinical sample. DNA nanobait structures identify multiple respiratory viruses simultaneously at the single-molecule level without reverse transcription or pre-amplification, and a bipedal DNA walker paired with strand displacement amplification achieves attomolar sensitivity with single-base resolution in 15 minutes. Beyond detection, spatially patterned icosahedral DNA nanocages carrying up to 30 neutralizing aptamers block the SARS-CoV-2 spike–ACE2 interaction across variants including Omicron, and cone-shaped DNA origami traps physically engulf pleomorphic virus particles larger than 100 nanometers, from influenza A to Zika and chikungunya. Star-shaped designer DNA architectures display aptamers in patterns that precisely match dengue virus surface antigens, functioning as both sensor and inhibitor.

Therapeutic applications extend deep into antibacterial medicine. TDNs delivering the antimicrobial peptide GL13K enhanced activity against E. coli and restored efficacy against Porphyromonas gingivalis, and an injectable thermosensitive hydrogel system co-delivering GL13K with C/EBPα small activating RNA is being developed for periodontitis, offering anti-inflammatory and osteogenic benefits alongside antibacterial action. TDN–clindamycin complexes lowered the minimum inhibitory concentration eightfold against methicillin-resistant S. aureus in infected bone defect models. DNA origami platforms carrying lysozyme within five wells and 14 targeting aptamers homed in on Bacillus subtilis and E. coli, while a bactericidal origami co-loading G4/hemin DNAzyme and levofloxacin breached bacterial membranes and accelerated infected wound healing in vivo. Antisense oligonucleotide delivery by TDNs has silenced biofilm-forming genes in Streptococcus mutans, and six-helix bundle structures co-delivering antisense RNA with silver ions showed synergistic killing of both gram-positive and gram-negative bacteria.

The technology is not without serious bottlenecks. DNA nanostructures depend on cations such as magnesium to neutralize electrostatic repulsion, so physiological media can trigger disassembly, and nucleases degrade unprotected structures rapidly. The hundreds of custom oligonucleotides required for origami are expensive, and laboratory fabrication resists scale-up to good manufacturing practice standards. Regulatory pathways remain ambiguous, batch-to-batch consistency is difficult to guarantee, and assembly byproducts arising from kinetic traps and thermodynamic competition depress yields. Pathogen-specific obstacles compound these challenges: biofilm extracellular matrices impede penetration even though TDNs achieve 44-fold stronger fluorescence at 20-micrometer biofilm depth than linear structures; RNA viruses mutate rapidly enough to escape single-target therapeutics, though multivalent, multi-epitope DNA scaffolds offer a hedge; and fungal cell walls of bewildering structural variability limit drug access, even as TDNs improve delivery of the antifungal peptide Histatin 5 against Candida albicans.

The outlook nevertheless points toward integration. The review’s authors propose stability benchmarks—structures retaining more than 80 percent integrity after 24 hours in human serum—alongside xenonucleic acid backbones, disulfide crosslinking, and oligolysine-PEG coatings to harden constructs against serum and nucleases. Double-blind validation across at least 500 clinical samples is framed as the gateway to diagnostic approval, while microfluidic chips, lyophilized paper-based formats, and artificial intelligence-assisted design promise point-of-care deployment by non-specialists. On the preventive side, DNA origami vaccine scaffolds have orchestrated antigen and CpG adjuvant spacing to elicit durable immune responses, DNA–RNA hybrid origami shows ribonuclease resistance suitable for mRNA vaccines, and inhalable DNA nano-adjuvants have activated lung-resident memory immunity against pneumonic plague in mice. Perhaps most compelling is the prospect of convergent platforms: single DNA nanostructures that detect an infection, deliver the therapeutic payload, and prime immunity—all from the same molecule that carries life’s code.

Subject of Research: Applications of DNA nanostructures in the detection, treatment, and prevention of pathogenic microorganisms

Article Title: Advances in DNA nanostructures for pathogenic microorganisms

Article References: Han, X., Zhang, J., Pang, S., Wei, G., Niu, J., Lu, Y., & Xi, J. (2026). Advances in DNA nanostructures for pathogenic microorganisms. Materials Today Bio, 40, Article 103591. https://doi.org/10.1016/j.mtbio.2026.103591

Image Credits: AI Generated

DOI: Not provided

Keywords: DNA nanostructures, DNA origami, tetrahedral DNA nanostructures, pathogen detection, antibacterial therapy, antiviral therapy, biosensors, drug delivery, biofilms, SARS-CoV-2, CRISPR diagnostics, nanomedicine